Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

Henk J. Out, Didi D.M. Braat, Bea M.E. Lintsen, Timur Gurgan, Orhan Bukulmez, Oya Gökmen, G#x00FC;rhan Keles, Pedro Caballero, José M. González, Francisco Fábregues, Juan Balasch, Roger Roulier

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

A prospective, randomized, double-blind, multicentre (n = 6) study was conducted to compare the influence of either a 150 or 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon®) on the number of oocytes retrieved and the total dose used in down-regulated women between 30 and 39 years of age undergoing ovarian stimulation. In all, 138 women were treated with recombinant FSH, 67 with 150 IU and 71 with 250 IU. The number of oocytes retrieved in the low-dose group was 9.1 compared to 10.6 in the high-dose group (not significant). In the 30-33 years of age class receiving the 250 IU dose, a surplus of 4.2 oocytes (14.8 versus 10.6) was found, whereas in the 37-39 age class nearly one oocyte more was retrieved in the 150 IU group (8.1 versus 7.4). The total dose used to reach the criterion for human chorionic gonadotrophin (HCG) administration was 1727 IU for the women treated with 150 IU daily and 2701 IU for the 250 IU treated women (P < 0.001). No significant relationships were found between serum FSH concentrations as obtained in the early follicular phase and the number of oocytes collected, or the total dose. It is concluded that in women between 30 and 39 years of age, the decline in number of oocytes retrieved with increasing age cannot be overcome by augmenting the daily dose of recombinant FSH from 150 to 250 IU.

Original languageEnglish (US)
Article number0150029
Pages (from-to)29-35
Number of pages7
JournalHuman Reproduction
Volume15
Issue number1
DOIs
StatePublished - 2000

Fingerprint

Ovulation Induction
Follicle Stimulating Hormone
Oocytes
Follicular Phase
Chorionic Gonadotropin
follitropin beta
Serum

Keywords

  • Age
  • IVF
  • Puregon
  • Recombinant FSH
  • Trial

ASJC Scopus subject areas

  • Reproductive Medicine
  • Rehabilitation
  • Obstetrics and Gynecology

Cite this

Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. / Out, Henk J.; Braat, Didi D.M.; Lintsen, Bea M.E.; Gurgan, Timur; Bukulmez, Orhan; Gökmen, Oya; Keles, G#x00FC;rhan; Caballero, Pedro; González, José M.; Fábregues, Francisco; Balasch, Juan; Roulier, Roger.

In: Human Reproduction, Vol. 15, No. 1, 0150029, 2000, p. 29-35.

Research output: Contribution to journalArticle

Out, HJ, Braat, DDM, Lintsen, BME, Gurgan, T, Bukulmez, O, Gökmen, O, Keles, GFC, Caballero, P, González, JM, Fábregues, F, Balasch, J & Roulier, R 2000, 'Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation', Human Reproduction, vol. 15, no. 1, 0150029, pp. 29-35. https://doi.org/10.1093/humrep/15.1.29
Out, Henk J. ; Braat, Didi D.M. ; Lintsen, Bea M.E. ; Gurgan, Timur ; Bukulmez, Orhan ; Gökmen, Oya ; Keles, G#x00FC;rhan ; Caballero, Pedro ; González, José M. ; Fábregues, Francisco ; Balasch, Juan ; Roulier, Roger. / Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. In: Human Reproduction. 2000 ; Vol. 15, No. 1. pp. 29-35.
@article{bbccc5d486f84e2890f8749e88b76ea0,
title = "Increasing the daily dose of recombinant follicle stimulating hormone (Puregon{\circledR}) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation",
abstract = "A prospective, randomized, double-blind, multicentre (n = 6) study was conducted to compare the influence of either a 150 or 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon{\circledR}) on the number of oocytes retrieved and the total dose used in down-regulated women between 30 and 39 years of age undergoing ovarian stimulation. In all, 138 women were treated with recombinant FSH, 67 with 150 IU and 71 with 250 IU. The number of oocytes retrieved in the low-dose group was 9.1 compared to 10.6 in the high-dose group (not significant). In the 30-33 years of age class receiving the 250 IU dose, a surplus of 4.2 oocytes (14.8 versus 10.6) was found, whereas in the 37-39 age class nearly one oocyte more was retrieved in the 150 IU group (8.1 versus 7.4). The total dose used to reach the criterion for human chorionic gonadotrophin (HCG) administration was 1727 IU for the women treated with 150 IU daily and 2701 IU for the 250 IU treated women (P < 0.001). No significant relationships were found between serum FSH concentrations as obtained in the early follicular phase and the number of oocytes collected, or the total dose. It is concluded that in women between 30 and 39 years of age, the decline in number of oocytes retrieved with increasing age cannot be overcome by augmenting the daily dose of recombinant FSH from 150 to 250 IU.",
keywords = "Age, IVF, Puregon, Recombinant FSH, Trial",
author = "Out, {Henk J.} and Braat, {Didi D.M.} and Lintsen, {Bea M.E.} and Timur Gurgan and Orhan Bukulmez and Oya G{\"o}kmen and G#x00FC;rhan Keles and Pedro Caballero and Gonz{\'a}lez, {Jos{\'e} M.} and Francisco F{\'a}bregues and Juan Balasch and Roger Roulier",
year = "2000",
doi = "10.1093/humrep/15.1.29",
language = "English (US)",
volume = "15",
pages = "29--35",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

AU - Out, Henk J.

AU - Braat, Didi D.M.

AU - Lintsen, Bea M.E.

AU - Gurgan, Timur

AU - Bukulmez, Orhan

AU - Gökmen, Oya

AU - Keles, G#x00FC;rhan

AU - Caballero, Pedro

AU - González, José M.

AU - Fábregues, Francisco

AU - Balasch, Juan

AU - Roulier, Roger

PY - 2000

Y1 - 2000

N2 - A prospective, randomized, double-blind, multicentre (n = 6) study was conducted to compare the influence of either a 150 or 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon®) on the number of oocytes retrieved and the total dose used in down-regulated women between 30 and 39 years of age undergoing ovarian stimulation. In all, 138 women were treated with recombinant FSH, 67 with 150 IU and 71 with 250 IU. The number of oocytes retrieved in the low-dose group was 9.1 compared to 10.6 in the high-dose group (not significant). In the 30-33 years of age class receiving the 250 IU dose, a surplus of 4.2 oocytes (14.8 versus 10.6) was found, whereas in the 37-39 age class nearly one oocyte more was retrieved in the 150 IU group (8.1 versus 7.4). The total dose used to reach the criterion for human chorionic gonadotrophin (HCG) administration was 1727 IU for the women treated with 150 IU daily and 2701 IU for the 250 IU treated women (P < 0.001). No significant relationships were found between serum FSH concentrations as obtained in the early follicular phase and the number of oocytes collected, or the total dose. It is concluded that in women between 30 and 39 years of age, the decline in number of oocytes retrieved with increasing age cannot be overcome by augmenting the daily dose of recombinant FSH from 150 to 250 IU.

AB - A prospective, randomized, double-blind, multicentre (n = 6) study was conducted to compare the influence of either a 150 or 250 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH, Puregon®) on the number of oocytes retrieved and the total dose used in down-regulated women between 30 and 39 years of age undergoing ovarian stimulation. In all, 138 women were treated with recombinant FSH, 67 with 150 IU and 71 with 250 IU. The number of oocytes retrieved in the low-dose group was 9.1 compared to 10.6 in the high-dose group (not significant). In the 30-33 years of age class receiving the 250 IU dose, a surplus of 4.2 oocytes (14.8 versus 10.6) was found, whereas in the 37-39 age class nearly one oocyte more was retrieved in the 150 IU group (8.1 versus 7.4). The total dose used to reach the criterion for human chorionic gonadotrophin (HCG) administration was 1727 IU for the women treated with 150 IU daily and 2701 IU for the 250 IU treated women (P < 0.001). No significant relationships were found between serum FSH concentrations as obtained in the early follicular phase and the number of oocytes collected, or the total dose. It is concluded that in women between 30 and 39 years of age, the decline in number of oocytes retrieved with increasing age cannot be overcome by augmenting the daily dose of recombinant FSH from 150 to 250 IU.

KW - Age

KW - IVF

KW - Puregon

KW - Recombinant FSH

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=0033963346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033963346&partnerID=8YFLogxK

U2 - 10.1093/humrep/15.1.29

DO - 10.1093/humrep/15.1.29

M3 - Article

C2 - 10611184

AN - SCOPUS:0033963346

VL - 15

SP - 29

EP - 35

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 1

M1 - 0150029

ER -